DBV Technologies’ (DBVT) “Market Outperform” Rating Reaffirmed at JMP Securities

DBV Technologies (NASDAQ:DBVT)‘s stock had its “market outperform” rating reiterated by equities researchers at JMP Securities in a report released on Friday,Benzinga reports. They currently have a $10.00 target price on the stock. JMP Securities’ target price would suggest a potential upside of 141.55% from the company’s previous close.

Several other research analysts have also issued reports on the stock. HC Wainwright increased their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. StockNews.com started coverage on shares of DBV Technologies in a report on Thursday. They set a “hold” rating for the company.

DBV Technologies Price Performance

DBVT stock traded up $0.31 during midday trading on Friday, hitting $4.14. The stock had a trading volume of 422,393 shares, compared to its average volume of 282,508. The business has a 50-day moving average of $3.29 and a two-hundred day moving average of $3.82. The firm has a market cap of $85.16 million, a price-to-earnings ratio of -0.92 and a beta of 0.64. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $9.49.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.